{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:22:05Z","timestamp":1783138925773,"version":"3.54.6"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107086","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:52:43Z","timestamp":1771573963000},"page":"107086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosis"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-3548","authenticated-orcid":false,"given":"Vito AG","family":"Ricigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriana","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giangaetano","family":"D'Aleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107086_bib0001","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/1352458520928795","article-title":"Exposure to natalizumab during pregnancy and lactation is safe - commentary","volume":"26","author":"Ciplea","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107086_bib0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00415-023-11955-0","article-title":"Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study","volume":"271","author":"Filippi","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107086_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105796","article-title":"Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration","volume":"90","author":"Gelissen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107086_bib0004","article-title":"Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths","volume":"14","author":"Graham","year":"2024","journal-title":"Neurol. Clin. Pr."},{"key":"10.1016\/j.msard.2026.107086_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jnnp-2023-331525","article-title":"Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis","volume":"95","author":"Haben","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107086_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107086_bib0007","article-title":"Effector T helper cells are selectively controlled during pregnancy and related to a postpartum relapse in multiple sclerosis","volume":"2","author":"Koetzier","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107086_bib0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107086_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420936166","article-title":"Sex effects across the lifespan in women with multiple sclerosis","volume":"13","author":"Krysko","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107086_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329657","article-title":"Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis","author":"Landi","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107086_bib0011","first-page":"1","article-title":"Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era","volume":"82","author":"Melo","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2026.107086_bib0012","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2026.107086_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.716548","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses","volume":"12","author":"Serra L\u00f3pez-Matencio","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107086_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054956","article-title":"The German multiple sclerosis and pregnancy registry: rationale, objective, design, and first results","volume":"14","author":"Thiel","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107086_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107086_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107086_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/13524585211052168","article-title":"Natalizumab concentrations during pregnancy in three patients with multiple sclerosis","volume":"28","author":"Toorop","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107086_bib0018","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/jnnp-2022-330467","article-title":"Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis","volume":"94","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107086_bib0019","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107086_bib0020","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s13311-017-0562-7","article-title":"Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding","volume":"14","author":"Voskuhl","year":"2017","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2026.107086_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/13524585231223390","article-title":"The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics","volume":"30","author":"Vukusic","year":"2024","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:23:40Z","timestamp":1781526220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"alternative-id":["S2211034826001227"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107086","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107086"}}